CoChat

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

Open access
Mantovani, Alessandro, Petracca, Graziana, Csermely, Alessandro, Beatrice, Giorgia, Targher, Giovanni · 2020 · Metabolites
Cited by 134

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Recent randomized controlled trials (RCTs) tested the efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors to specifically treat nonalcoholic fatty liver disease (NAFLD). We systematically searched three electronic databases (up to 31 October 2020) for identifying placebo-controlled or head-to-head RCTs that used SGLT-2 inhibitors for treatment of NAFLD. No published RCTs with paired liver biopsy data were available for the meta-analysis. Primary outcome measures were changes in serum liver enzyme levels and liver fat content on imaging techniques. Overall, we included a total of twelve RCTs testing the efficacy of dapagliflozin (n = six RCTs), empagliflozin (n = three RCTs), ipragliflozin (n = two RCTs) or canagliflozin (n = one RCT) to specifically treat NAFLD for a median period of 24 weeks with aggregate data on 850 middle-aged overweight or obese individuals with NAFLD (90% with type 2 diabetes). Compared to placebo/reference therapy, treatment with SGLT-2 inhibitors significantly decreased serum alanine aminotransferase (weighted mean differences (WMD): −10.0 IU/L, 95%CI −12.2 to −7.79 IU/L; I2 = 10.5%) and gamma-glutamyltransferase levels (WMD: −14.49 IU/L, 95%CI −19.35 to −9.63 IU/L, I2 = 38.7%), as well as the absolute percentage of liver fat content on magnetic resonance-based techniques (WMD: −2.05%, 95%CI −2.61 to −1.48%; I2 = 0%). In conclusion, SGLT-2 inhibitors seem to be a promising treatment option for NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/metabo11010022

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 30

  1. Non-alcoholic Fatty Liver Disease Study Group, Lonardo, A., Bellentani, S., Argo, C.K., Ballestri, S., Byrne, C.D., Caldwell, S.H., Cortez-Pinto, H., Grieco, A., and Machado, M.V. (2015). Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig. Liver Dis., 47, 997–1006. · DOI · Paper page
  2. Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C.D., and Targher, G. (2020). Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. · DOI · Paper page
  3. Budd, 2020, Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease, Curr. Diab. Rep., 20, 59, 10.1007/s11892-020-01349-1 · DOI
  4. Cusi, 2020, A diabetologist’s perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions, Liver Int., 40, 82, 10.1111/liv.14350 · DOI · Paper page
  5. Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X · DOI · Paper page
  6. Scheen, 2020, Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus, Nat. Rev. Endocrinol., 16, 556, 10.1038/s41574-020-0392-2 · DOI · Paper page
  7. Schernthaner, 2016, EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus, Clin. Ther., 38, 1288, 10.1016/j.clinthera.2016.04.037 · DOI
  8. Zelniker, 2020, Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review, J. Am. Coll. Cardiol., 75, 435, 10.1016/j.jacc.2019.11.036 · DOI
  9. Wu, 2016, Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis, Lancet Diabetes Endocrinol., 4, 411, 10.1016/S2213-8587(16)00052-8 · DOI · Paper page
  10. Zelniker, 2020, Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review, J. Am. Coll. Cardiol., 75, 422, 10.1016/j.jacc.2019.11.031 · DOI · Paper page
  11. Dougherty, 2021, A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease, Ann. Pharmacother., 55, 65, 10.1177/1060028020935105 · DOI · Paper page
  12. Ito, 2017, Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial, Diabetes Care, 40, 1364, 10.2337/dc17-0518 · DOI · Paper page
  13. Shimizu, 2019, Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease, Diabetes Obes. Metab., 21, 285, 10.1111/dom.13520 · DOI · Paper page
  14. Johansson, 2020, Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes, Diabetes Obes. Metab., 22, 1094, 10.1111/dom.14004 · DOI · Paper page
  15. Taheri, 2020, Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial, Adv. Ther., 37, 4697, 10.1007/s12325-020-01498-5 · DOI · Paper page
  16. Han, E., Lee, Y.H., Lee, B.W., Kang, E.S., and Cha, B.S. (2020). Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. J. Clin. Med., 9. · DOI
  17. Kinoshita, 2020, Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study, J. Diabetes Investig., 11, 1612, 10.1111/jdi.13279 · DOI
  18. Gallo, 2020, Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials, Diabetes Ther., 11, 1849, 10.1007/s13300-020-00867-1 · DOI
  19. Li, 2018, Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials, J. Pharm. Pharm. Sci., 21, 222, 10.18433/jpps29831 · DOI · Paper page
  20. Raj, 2019, SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review, World J. Diabetes, 10, 114, 10.4239/wjd.v10.i2.114 · DOI · Paper page
  21. Scheen, 2019, Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications, Diabetes Metab., 45, 213, 10.1016/j.diabet.2019.01.008 · DOI · Paper page
  22. Ji, W., Zhao, M., Wang, M., Yan, W., Liu, Y., Ren, S., Lu, J., Wang, B., and Chen, L. (2017). Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS ONE, 12. · DOI
  23. Swe, 2019, Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats, Clin. Sci., 133, 2415, 10.1042/CS20190863 · DOI
  24. Caussy, 2018, Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials, Hepatology, 68, 763, 10.1002/hep.29797 · DOI · Paper page
  25. Targher, 2016, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis, J. Hepatol., 65, 589, 10.1016/j.jhep.2016.05.013 · DOI · Paper page
  26. Mantovani, 2018, Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis, Metabolism, 79, 64, 10.1016/j.metabol.2017.11.003 · DOI · Paper page
  27. Lonardo, 2019, Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps, Hepatology, 70, 1457, 10.1002/hep.30626 · DOI · Paper page
  28. Markham, 2014, Luseogliflozin: First global approval, Drugs, 74, 945, 10.1007/s40265-014-0230-8 · DOI
  29. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat. Med., 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  30. Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, 1088, 10.2307/2533446 · DOI · Paper page

Cited by

See all 134

Metadata

Authors
Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G.
Venue
Metabolites
Publisher
MDPI AG
Published
2020-12-30
Volume
11
Issue
1
Pages
22
ISSN
2218-1989 (ISSN-L)
OpenAlex
W3115762316
Cited by
134
References
20
FWCI
4.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.3390/metabo11010022
The paper
Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G. (2020). Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites. https://doi.org/10.3390/metabo11010022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.